Background/Objectives: Frontal fibrosing alopecia (FFA) is a scarring alopecia with an unclear aetiology, primarily affecting postmenopausal women. This study aims to identify potential risk factors contributing to FFA development and progression, as well as provide a clinical profile to aid in the differential diagnosis. Methods: The study included 19 women diagnosed with FFA. The participants completed a 20-question survey based on a literature review of potential risk factors. Statistical analyses were performed to investigate the associations between patient characteristics and FFA. Results: All patients were female and their mean age was 60.58 years (SD = 12.81). In 63.1% of the cases, FFA onset occurred postmenopause, with a mean latency of 8.17 years. In the majority of cases, the diagnostic delay exceeded five years. The average menarche age was 13.68 years (SD = 2.06), whereas late menarche (≥15 years) was found in two subjects. A history of reproductive organ or breast malignancy was reported by 42.1% of the patients, which frequently required surgery. Most subjects did not receive hormone replacement therapy, or hormonal contraception. The most prevalent comorbidity was hypothyroidism (89.47%). Although smoking was rare among the subjects, hair colouring was quite common, yet no participant underwent scalp aesthetic procedures. In 47.4% of cases, scalp itching or pain was present. Sunscreens were frequently used, mostly on a daily or seasonal basis. Conclusions: FFA predominantly affects women in their early 60s, often following the menopause. In our study, a tendency toward an early menopause and an above-average menarche age of the subjects was observed. In the analysed group, only reproductive and breast cancers were reported, which requires further investigation. Frequent β-blocker use, second only to levothyroxine, may suggest that they play a role in FFA pathogenesis. Itching and pain of the scalp may contribute to the correct diagnosis, although these symptoms are not universal. Moreover, sunscreens were indicated as a potential trigger, yet avoiding them should not be routinely recommended due to the risk of carcinogenesis. The variability in the diagnostic delay emphasises the need for increasing clinician awareness and conducting further research.

Granuloma Faciale is a rare and chronic skin disease. Although many therapeutic options have been described, general and topical treatment often does not bring satisfactory results and invasive modalities may result in scarring or hyperpigmentation. We report a case of Granuloma faciale in a 50-year‑old man. He reported to our clinic with reddish papules on the forehead. Histopathological examination confirmed a diagnosis. The treatment included clobetasol propionate followed by tacrolimus with no improvement. The patient was then given intralesional triamcinolone (0.01 g/ml in doses of 0.6ml). Four procedures with 6-weeks intervals were performed. A complete resolution of the lesion with no adverse effects was observed. Although the lesions are difficult to treat with a tendency to recur, they can be successfully treated with intralesional triamcinolone with perfect aesthetic outcome. Such treatment shall be considered a first‑line therapy due to highly satisfying cosmetic results, cost‑effectiveness and minimal risk of adverse effects.